JP2012512251A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012512251A5 JP2012512251A5 JP2011542333A JP2011542333A JP2012512251A5 JP 2012512251 A5 JP2012512251 A5 JP 2012512251A5 JP 2011542333 A JP2011542333 A JP 2011542333A JP 2011542333 A JP2011542333 A JP 2011542333A JP 2012512251 A5 JP2012512251 A5 JP 2012512251A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- compound
- alkyl
- disorder
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 19
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 9
- 101710164184 Synaptic vesicular amine transporter Proteins 0.000 claims 5
- 102100034333 Synaptic vesicular amine transporter Human genes 0.000 claims 5
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims 3
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 3
- 125000006725 C1-C10 alkenyl group Chemical group 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 208000024714 major depressive disease Diseases 0.000 claims 3
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 102000006441 Dopamine Plasma Membrane Transport Proteins Human genes 0.000 claims 2
- 108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 claims 2
- 102000008092 Norepinephrine Plasma Membrane Transport Proteins Human genes 0.000 claims 2
- 108010049586 Norepinephrine Plasma Membrane Transport Proteins Proteins 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 claims 2
- 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000012672 seasonal affective disease Diseases 0.000 claims 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- 208000020685 sleep-wake disease Diseases 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims 1
- -1 -OR 1 Chemical group 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 150000003841 chloride salts Chemical class 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 229960003638 dopamine Drugs 0.000 claims 1
- 208000024732 dysthymic disease Diseases 0.000 claims 1
- 201000003104 endogenous depression Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004404 heteroalkyl group Chemical group 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000036651 mood Effects 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 229960002748 norepinephrine Drugs 0.000 claims 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 229940076279 serotonin Drugs 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13806208P | 2008-12-16 | 2008-12-16 | |
| US61/138,062 | 2008-12-16 | ||
| PCT/US2009/068016 WO2010075064A1 (en) | 2008-12-16 | 2009-12-15 | Triple reuptake inhibitors and methods of their use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015097841A Division JP6218774B2 (ja) | 2008-12-16 | 2015-05-13 | トリプル再取込み阻害剤及びそれらの使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012512251A JP2012512251A (ja) | 2012-05-31 |
| JP2012512251A5 true JP2012512251A5 (enExample) | 2013-02-14 |
| JP5749176B2 JP5749176B2 (ja) | 2015-07-15 |
Family
ID=41786405
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011542333A Expired - Fee Related JP5749176B2 (ja) | 2008-12-16 | 2009-12-15 | トリプル再取込み阻害剤及びそれらの使用方法 |
| JP2015097841A Expired - Fee Related JP6218774B2 (ja) | 2008-12-16 | 2015-05-13 | トリプル再取込み阻害剤及びそれらの使用方法 |
| JP2017155298A Expired - Fee Related JP6321274B2 (ja) | 2008-12-16 | 2017-08-10 | トリプル再取込み阻害剤及びそれらの使用方法 |
| JP2018072080A Pending JP2018127472A (ja) | 2008-12-16 | 2018-04-04 | トリプル再取込み阻害剤及びそれらの使用方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015097841A Expired - Fee Related JP6218774B2 (ja) | 2008-12-16 | 2015-05-13 | トリプル再取込み阻害剤及びそれらの使用方法 |
| JP2017155298A Expired - Fee Related JP6321274B2 (ja) | 2008-12-16 | 2017-08-10 | トリプル再取込み阻害剤及びそれらの使用方法 |
| JP2018072080A Pending JP2018127472A (ja) | 2008-12-16 | 2018-04-04 | トリプル再取込み阻害剤及びそれらの使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US8592608B2 (enExample) |
| EP (1) | EP2370405B1 (enExample) |
| JP (4) | JP5749176B2 (enExample) |
| CN (2) | CN105384676B (enExample) |
| AU (1) | AU2009330355B2 (enExample) |
| CA (1) | CA2746055C (enExample) |
| ES (1) | ES2421171T3 (enExample) |
| WO (1) | WO2010075064A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105384676B (zh) * | 2008-12-16 | 2019-05-07 | 桑诺维恩药品公司 | 三重再摄取抑制剂及其应用方法 |
| CN102417475A (zh) * | 2010-09-28 | 2012-04-18 | 江苏恒瑞医药股份有限公司 | 氮杂双环辛烷类衍生物、其制备方法及其在医药上的应用 |
| WO2012142067A2 (en) * | 2011-04-13 | 2012-10-18 | Sunovion Pharmaceuticals Inc. | Formulations, salts, and solid forms of substituted cyclohexylmethanamines, processes for preparation, and uses thereof |
| ITMI20120192A1 (it) * | 2012-02-13 | 2013-08-14 | Dipharma Francis Srl | Procedimento per la preparazione di un inibitore delle proteasi virali e suoi intermedi |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4042707A (en) * | 1976-02-19 | 1977-08-16 | E. I. Du Pont De Nemours And Company | 3α-Arylhydroisoindoles |
| US4529736A (en) | 1982-07-28 | 1985-07-16 | American Cyanamid Company | 3a-(Substituted phenyl)-2,3,3a,4,7,7a-hexahydro[or 3a-(substituted-phenyl)octahydro]-4,7-alkano-1H-isoindoles for treating depression in warm-blooded animals |
| EP0100426A1 (en) * | 1982-07-28 | 1984-02-15 | American Cyanamid Company | 3a-(substituted-phenyl)-hexaloctahydro-4,7-alkanoisoindoles |
| DE3371082D1 (de) * | 1982-09-09 | 1987-05-27 | Hoffmann La Roche | Thieno(2,3-e)-1,2-thiazine derivatives |
| US4544665A (en) * | 1983-11-21 | 1985-10-01 | American Cyanamid Company | 1-Aryl-3-azabicyclo[3.2.0]heptanes |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| EP1874298A4 (en) | 2005-03-08 | 2009-08-05 | Dov Pharmaceutical Inc | METHOD AND COMPOSITIONS FOR THE PREPARATION, FORMULATION AND USE OF 1-ARYL-3-AZABICYCLO [3,1,0] HEXANES |
| WO2006114402A1 (en) * | 2005-04-25 | 2006-11-02 | Biovitrum Ab (Publ) | Substituted octahydroisoindoles as antagonists of melanin concentrating hormone receptor 1 (mch1r) |
| US7476679B2 (en) * | 2005-07-26 | 2009-01-13 | Research Triangle Institute | Octahydroisoquinoline compounds as opioid receptor modulators |
| US20070082939A1 (en) * | 2005-07-26 | 2007-04-12 | Lippa Arnold S | Methods and compositions for the treatment of neuropathies and related disorders |
| CN104059013B8 (zh) * | 2005-07-27 | 2016-09-21 | 纽若范斯有限公司 | 1-芳基-3-氮杂二环[3.1.0]己烷：其制备方法和用于治疗神经精神障碍的用途 |
| CN105384676B (zh) * | 2008-12-16 | 2019-05-07 | 桑诺维恩药品公司 | 三重再摄取抑制剂及其应用方法 |
-
2009
- 2009-12-15 CN CN201510671770.3A patent/CN105384676B/zh not_active Expired - Fee Related
- 2009-12-15 CA CA2746055A patent/CA2746055C/en active Active
- 2009-12-15 JP JP2011542333A patent/JP5749176B2/ja not_active Expired - Fee Related
- 2009-12-15 ES ES09795857T patent/ES2421171T3/es active Active
- 2009-12-15 AU AU2009330355A patent/AU2009330355B2/en not_active Ceased
- 2009-12-15 US US13/139,967 patent/US8592608B2/en active Active
- 2009-12-15 EP EP09795857.3A patent/EP2370405B1/en not_active Not-in-force
- 2009-12-15 CN CN200980156733.1A patent/CN102317261B/zh not_active Expired - Fee Related
- 2009-12-15 WO PCT/US2009/068016 patent/WO2010075064A1/en not_active Ceased
-
2013
- 2013-10-24 US US14/062,626 patent/US9133117B2/en not_active Expired - Fee Related
-
2015
- 2015-05-13 JP JP2015097841A patent/JP6218774B2/ja not_active Expired - Fee Related
- 2015-09-10 US US14/850,338 patent/US9850204B2/en active Active
-
2017
- 2017-08-10 JP JP2017155298A patent/JP6321274B2/ja not_active Expired - Fee Related
- 2017-11-20 US US15/817,760 patent/US10428021B2/en not_active Expired - Fee Related
-
2018
- 2018-04-04 JP JP2018072080A patent/JP2018127472A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2011119990A (ru) | Циклоалкиламины в качестве ингибиторов повторного поглощения моноамина | |
| ES2432102T3 (es) | Compuestos con actividad combinada en SERT, 5-HT3 y 5-HT1A | |
| JP2010529045A5 (enExample) | ||
| JP5270167B2 (ja) | （ｒ）−８−クロロ−１−メチル−２，３，４，５−テトラヒドロ−１ｈ−３−ベンザゼピン塩酸塩の結晶形 | |
| JP2012530779A5 (enExample) | ||
| JP2009527462A5 (enExample) | ||
| PH12012500951A1 (en) | Substituted benzamide derivatives | |
| JP2012512251A5 (enExample) | ||
| RU2009149292A (ru) | Циклоалкиламины, содержащие в качестве заместителя фенил, как ингибиторы обратного захвата моноаминов | |
| RU2009124541A (ru) | Тозилатная соль терапевтического соединения и ее фармацевтические композиции | |
| JP6236077B2 (ja) | 持続時間が超短期、短期、または中期の非対称性逆転可能神経筋遮断物質 | |
| JP2005535592A5 (enExample) | ||
| ES2968840T3 (es) | Compuestos de aminocarbonilcarbamato y su uso en el tratamiento de trastornos hipercinéticos tales como el TDAH | |
| JP2018505204A5 (enExample) | ||
| JP2008503523A5 (enExample) | ||
| RU2016131875A (ru) | Производные n-фениллактама, способные стимулировать нейрогенез, и их применение при лечении заболеваний нервной системы | |
| JP2010522710A5 (enExample) | ||
| NZ589497A (en) | Process for the synthesis of arformoterol | |
| JP2012526832A5 (enExample) | ||
| JP2011525185A5 (enExample) | ||
| JP2013503880A5 (enExample) | ||
| JP2012517437A5 (enExample) | ||
| JP2014511897A5 (enExample) | ||
| JP2011506463A5 (enExample) | ||
| TW200800148A (en) | Use of agomelatine in obtaining medicaments intended for the treatment of sleep disorders in the depressed patient |